Lenalidomide g.l.

Package leaflet: Information for the patient

Lenalidomide G.L., 5 mg, hard capsules
Lenalidomide G.L., 10 mg, hard capsules
Lenalidomide G.L., 15 mg, hard capsules
Lenalidomide G.L., 25 mg, hard capsules
Lenalidomidum
Please read this leaflet carefully before taking this medicine, because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, please ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including any not listed in this leaflet, please tell your doctor or pharmacist. See section 4.

Contents of the leaflet

1. What Lenalidomide G.L. is and what it is used for
2. Important information before taking Lenalidomide G.L.
3. How to take Lenalidomide G.L.
4. Possible side effects
5. How to store Lenalidomide G.L.
6. Contents of the pack and other information

1. What Lenalidomide G.L. is and what it is used for

What Lenalidomide G.L. is
Lenalidomide G.L. contains the active substance "lenalidomide". This medicine belongs to a group of medicines that affect the function of the immune system.
What Lenalidomide G.L. is used for
Lenalidomide G.L. is used in adult patients for the treatment of:

• multiple myeloma,
• myelodysplastic syndromes,
• mantle cell lymphoma,
• follicular lymphoma.

Multiple myeloma
Multiple myeloma is a type of cancer that affects a certain type of white blood cells called plasma cells. These cells accumulate in the bone marrow and divide uncontrollably. This may lead to damage of bones and kidneys.
Multiple myeloma is generally incurable. However, it is possible to achieve temporary significant reduction or elimination of signs and symptoms of the disease. This is called "remission".
Newly diagnosed multiple myeloma — in patients after bone marrow transplantation
In this indication, Lenalidomide G.L. is used as monotherapy for maintenance treatment following achievement of an adequate response after transplantation.
Newly diagnosed multiple myeloma – in patients who are not eligible for bone marrow transplantation
Lenalidomide G.L. is taken in combination with other medicines, including:

• a chemotherapy medicine called "bortezomib";
• an anti-inflammatory medicine called "dexamethasone";
• a chemotherapy medicine called "melphalan"; and
• an immunosuppressive medicine called "prednisone".
  The patient starts treatment with additional medicines and then continues with Lenalidomide G.L. alone.

If the patient is 75 years of age or older, or has moderate to severe kidney problems, the doctor will perform thorough examinations before starting treatment.
Multiple myeloma – in previously treated patients
Lenalidomide G.L. is taken in combination with an anti-inflammatory medicine called "dexamethasone".
Lenalidomide may stop the progression of signs and symptoms of multiple myeloma. It has also been shown to delay relapse of multiple myeloma after treatment.
Myelodysplastic syndromes (MDS)
Myelodysplastic syndromes (MDS) are a group of different blood and bone marrow disorders. Abnormal blood cells are present, which do not function properly. Patients may experience various subjective and objective symptoms, including low number of red blood cells (anaemia), need for blood transfusions, and risk of infection.
Lenalidomide G.L. as monotherapy is used in the treatment of adult patients diagnosed with MDS, if all the following conditions are met:

• the patient requires regular blood transfusions due to low number of red blood cells ("transfusion-dependent anaemia");
• the patient has an abnormality in bone marrow cells called "isolated cytogenetic abnormality of deletion 5q". This means that the patient's body does not produce enough healthy blood cells;
• the patient has previously received other treatments that were inappropriate or insufficiently effective.

Taking Lenalidomide G.L. may lead to an increase in the number of healthy red blood cells produced by the body, by reducing the number of abnormal cells:

• this may lead to a reduction in the number of required blood transfusions. It may be possible that transfusions will no longer be needed.
  Mantle cell lymphoma (MCL)
  MCL is a cancer of part of the immune system (lymphatic tissue). It attacks a certain type of white blood cells called B-lymphocytes or B-cells. Mantle cell lymphoma is a disease characterised by uncontrolled growth of B-lymphocytes, leading to their accumulation in lymphatic tissue, bone marrow or blood.

Lenalidomide G.L. as monotherapy is used in the treatment of adult patients who have been previously treated with other medicines.
Follicular lymphoma (FL)
FL is a slowly growing malignant tumour that attacks B-lymphocytes. These are a type of white blood cells that help the body fight infections. In patients with FL, excessive numbers of B-lymphocytes may accumulate in the blood, bone marrow, lymph nodes and spleen.
Lenalidomide G.L. is taken together with another medicine called "rituximab" in the treatment of adult patients with previously treated follicular lymphoma.
How Lenalidomide G.L. works
Lenalidomide G.L. works by affecting the function of the immune system and directly attacking tumour cells. The medicine works in several different ways:

• by inhibiting the growth of tumour cells;
• by inhibiting the development of blood vessels in the tumour;
• by stimulating part of the immune system to attack tumour cells.

2. Important information before taking Lenalidomide G.L.
Before starting treatment with Lenalidomide G.L., please read carefully the leaflets of all medicinal products taken in combination with Lenalidomide G.L.
Do not take Lenalidomide G.L. if:

• the patient is pregnant, suspects she may be pregnant, or plans to have a child, because Lenalidomide G.L. is expected to be harmful to the unborn child (see section 2 "Pregnancy, breastfeeding and contraception – information for women and men").
• the patient is of childbearing potential unless she uses all required contraceptive measures (see section 2 "Pregnancy, breastfeeding and contraception – information for women and men"). If the patient is of childbearing potential, the doctor will always document the use of necessary contraceptive measures when prescribing the medicine and ensure the patient is aware of them.
• the patient is allergic to lenalidomide or any of the other ingredients of this medicine (listed in section 6). If allergy is suspected, please consult your doctor for advice.

Do not use Lenalidomide G.L. if any of the above apply to you.
If in doubt, please consult your doctor.
Warnings and precautions
Please discuss with your doctor, pharmacist or nurse if you:

• have previously had blood clots – this means an increased risk of blood clots forming in veins and arteries during treatment;
• have any signs of infection, such as cough or fever;
• currently have or have previously had a viral infection, particularly chickenpox or shingles, hepatitis B, or HIV. If in doubt, please consult your doctor. Treatment with Lenalidomide G.L. may cause reactivation of viruses in patients previously infected, leading to recurrence of infection. Your doctor will check whether you have previously had hepatitis B;
• have kidney problems – your doctor may adjust the dose of Lenalidomide G.L.;
• have had a heart attack (heart attack), have ever had a blood clot, if you smoke, have high blood pressure or high cholesterol levels;
• experienced allergic symptoms while taking thalidomide (another medicine used in the treatment of multiple myeloma), such as rash, itching, swelling, dizziness or difficulty breathing;
• have previously had a combination of any of the following symptoms: widespread rash, skin redness, high body temperature, flu-like symptoms, increased liver enzyme activity, blood abnormalities (eosinophilia), enlarged lymph nodes – these are symptoms of a severe skin reaction called drug rash with eosinophilia and systemic symptoms, also known as "DRESS" or "drug hypersensitivity syndrome" (see also section 4 "Possible side effects").

If any of the above apply to you, please consult your doctor, pharmacist or nurse.
If at any time during or after treatment you experience:

• vision disturbances, loss of vision or double vision, difficulty speaking, weakness of arm or leg, change in walking or balance disturbances, persistent tingling, reduced sensation or loss of sensation, memory loss or disorientation, please inform your doctor or nurse immediately. These may be symptoms of a severe and potentially fatal brain disease called progressive multifocal leukoencephalopathy (PML). If you had such symptoms before treatment with Lenalidomide G.L., inform your doctor of any changes.
• shortness of breath, fatigue, dizziness, chest pain, rapid heartbeat or swelling of legs or ankles. These may be symptoms of a serious condition known as pulmonary hypertension (see section 4).

Tests and examinations
Before and during treatment with Lenalidomide G.L., you will have regular blood tests performed, because Lenalidomide G.L. may reduce the number of blood cells that help fight infection (white blood cells) and help blood to clot (platelets).
Your doctor will ask you to have blood tests:

• before treatment,
• weekly for the first 8 weeks of treatment,
• then at least once a month.

Before starting lenalidomide treatment and during treatment, you may be assessed for circulatory and respiratory problems.
Patients with MDS taking Lenalidomide G.L.
If you have myelodysplastic syndromes, there is an increased chance of developing a serious disease called acute myeloid leukaemia. In addition, it is not known how Lenalidomide G.L. affects the likelihood of developing acute myeloid leukaemia. Therefore, your doctor may perform tests and check for signs that may better predict the risk of acute myeloid leukaemia during treatment with Lenalidomide G.L.
Patients with MCL taking Lenalidomide G.L.
Your doctor will ask you to have blood tests:

• before treatment,
• weekly for the first 8 weeks (2 cycles) of treatment,
• then every 2 weeks during cycles 3 and 4 (more information in section 3 "Treatment cycle"),
• then at the beginning of each cycle and
• at least once a month.

Patients with FL taking Lenalidomide G.L.
Your doctor will ask you to have blood tests:

• before treatment,
• weekly for the first 3 weeks (1 cycle) of treatment,
• then every 2 weeks during cycles 2 to 4 (more information in section 3 "Treatment cycle"),
• then at the beginning of each cycle and
• at least once a month.

Your doctor may perform a test to determine whether you have a large amount of tumour tissue in your body, including in the bone marrow. This may lead to a situation where tumour tissue begins to die and causes abnormal increases in various substances in the blood, which may lead to kidney failure (a condition called tumour lysis syndrome).
Your doctor may examine you to check for skin changes, such as red spots or rash.
Your doctor may change the dose of Lenalidomide G.L. or interrupt treatment based on the results of your blood tests and your general condition. If the disease has been recently diagnosed, your doctor may also assess treatment based on your age and other conditions you may have had in the past.
Blood donation
During treatment and for at least 7 days after treatment ends, you must not donate blood.
Children and adolescents
Lenalidomide G.L. is not recommended for use in children and adolescents under 18 years of age.
Elderly patients and patients with kidney disease
If you are 75 years of age or older, or have moderate to severe kidney problems, your doctor will perform thorough examinations before starting treatment.
Lenalidomide G.L. and other medicines
Please tell your doctor or nurse about all medicines you are currently taking or have recently taken. This is necessary because Lenalidomide G.L. may affect the action of other medicines. Other medicines may also affect the action of Lenalidomide G.L.
In particular, please inform your doctor or nurse if you are taking the following medicines:

• certain medicines used to prevent pregnancy, such as oral contraceptives, because they may stop working;
• certain medicines used for heart problems – such as digoxin;
• certain medicines used to thin the blood – such as warfarin.

Pregnancy, breastfeeding and contraception – information for women and men
Pregnancy
For women taking Lenalidomide G.L.

• Do not take Lenalidomide G.L. if you are pregnant, because it is expected to be harmful to the unborn child.
• Women must not become pregnant while taking Lenalidomide G.L. Therefore, women of childbearing potential must use an effective method of contraception (see "Contraception").
• If you become pregnant while being treated with Lenalidomide G.L., you must stop treatment immediately and inform your doctor.

For men taking Lenalidomide G.L.

• If the female partner of a man being treated with Lenalidomide G.L. becomes pregnant, she should inform the doctor immediately. The partner should seek medical advice.
• Men must also use an effective method of contraception (see "Contraception").

Breastfeeding
Do not breastfeed while taking Lenalidomide G.L., because it is not known whether lenalidomide passes into human milk.
Contraception
Women taking Lenalidomide G.L.
Before starting treatment, please ask your doctor about the possibility of becoming pregnant, even if you consider it unlikely.
Women of childbearing potential:

• will have pregnancy tests performed under the supervision of a doctor (before each treatment, at least every 4 weeks during treatment and at least 4 weeks after treatment ends), unless the fallopian tubes have been cut and sealed to prevent the egg from reaching the uterus (tubal sterilisation), AND
• must use effective methods of contraception for at least 4 weeks before starting treatment, during treatment and for at least 4 weeks after treatment ends. Your doctor will advise you on appropriate contraceptive methods.

Men taking Lenalidomide G.L.
Lenalidomide G.L. passes into human sperm. If a woman is pregnant or may become pregnant and is not using an effective method of contraception, her partner should use a condom during treatment and for at least 7 days after treatment ends. This also applies to men who have had a vasectomy. During treatment and for at least 7 days after treatment ends, you must not donate sperm.
Driving and using machines
Do not drive or operate machinery if you experience dizziness, fatigue, drowsiness, balance disturbances due to vertigo or blurred vision after taking Lenalidomide G.L.
Lenalidomide G.L. contains lactose.
Lenalidomide G.L. contains lactose. If you have been previously diagnosed with intolerance to certain sugars, you should contact your doctor before taking Lenalidomide G.L.
This medicine contains less than 1 mmol sodium (23 mg) per capsule, i.e. the medicine is considered "sodium-free".

3. How to take Lenalidomide G.L.

Lenalidomide G.L. must be administered by medical professionals experienced in the treatment of multiple myeloma, MDS, MCL or FL.

• When Lenalidomide G.L. is used to treat multiple myeloma in patients who are not eligible for bone marrow transplantation or who have previously received other treatment, the medicine should be used in combination with other medicines (see section 1 "Why Lenalidomide G.L. is used").
• When Lenalidomide G.L. is used to treat multiple myeloma in patients after bone marrow transplantation, or in patients with MDS or MCL, the medicine should be used as monotherapy.
• When Lenalidomide G.L. is used to treat follicular lymphoma, it should be taken together with another medicine called "rituximab".

Lenalidomide G.L. should always be taken as directed by the physician. In case of doubt, consult your doctor or pharmacist.
If the patient is taking Lenalidomide G.L. together with other medicines, they should read the package leaflet included with those medicines to obtain information about their use and effects.

Treatment cycle
Lenalidomide G.L. is taken on specific days over a period of three weeks (21 days).

• Each 21-day period is called a treatment cycle.

• Depending on the day of the cycle, the patient may take one or more medicines. However, on certain days the patient will not take any medicines.

• After completion of each 21-day cycle, the patient should start a new 21-day cycle.
  OR
  Lenalidomide G.L. is taken on specific days over a period of four weeks (28 days).

• Each 28-day period is called a treatment cycle.

• Depending on the day of the cycle, the patient may take one or more medicines. However, on certain days the patient will not take any medicines.

• After completion of each 28-day cycle, the patient should start a new 28-day cycle.

Recommended dose of Lenalidomide G.L.
Before starting treatment, the doctor will inform the patient:

• how much Lenalidomide G.L. they should take;
• how many other medicines they should take in combination with Lenalidomide G.L., if additional medicines are required;
• on which days of the cycle to take which medicines.

How and when to take Lenalidomide G.L.

• Swallow the capsule whole, preferably with water.
• Do not crush, open or chew the capsules. If powder from a damaged Lenalidomide G.L. capsule comes into contact with the skin, wash the skin immediately and thoroughly with soap and water.
• Healthcare professionals, caregivers and family members should wear disposable gloves when handling the blister pack or capsules. Gloves should be carefully removed to avoid skin exposure, placed in a sealed polyethylene plastic bag, and disposed of according to local regulations. Hands should then be washed thoroughly with soap and water. Women who are pregnant or suspect they may be pregnant should not handle the blister pack or capsules.
• Capsules may be taken with or without food.
• Lenalidomide G.L. should be taken at approximately the same time each day on which the dose is scheduled.

How to take this medicine
To remove the capsule from the blister pack:

• press on the capsule from one side only and push it through the foil;
• do not press on the center of the capsule, as this may damage it.

Duration of treatment with Lenalidomide G.L.
Lenalidomide G.L. is used in treatment cycles; each cycle lasts 21 or 28 days (see above, "Treatment cycle"). Treatment cycles should continue until the doctor decides to discontinue the medicine.

Taking more than the recommended dose of Lenalidomide G.L.
If more than the prescribed dose of Lenalidomide G.L. has been taken, contact the doctor immediately.

Missed dose of Lenalidomide G.L.
If a dose of Lenalidomide G.L. has been missed at the scheduled time and

• less than 12 hours have passed: take the capsule immediately;
• more than 12 hours have passed: do not take the missed capsule. Take the next scheduled dose at the usual time.

If you have any further questions about the use of this medicine, consult your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine may cause side effects, although not everyone gets them.

If any of the following serious side effects occur, stop taking Lenalidomide G.L. and seek immediate medical attention – immediate treatment may be required:

• hives, rash, swelling of the eyes, lips or face, difficulty breathing or wheezing, which may be symptoms of serious allergic reactions known as angioedema and anaphylactic reaction;
• severe allergic reaction possibly starting as a rash in one area, spreading over the whole body and associated with significant skin peeling (Stevens-Johnson syndrome and/or toxic epidermal necrolysis);
• widespread rash, high fever, increased liver enzyme activity, blood abnormalities (eosinophilia), swollen lymph nodes and involvement of other organs (drug reaction with eosinophilia and systemic symptoms, also known as “DRESS” or “drug hypersensitivity syndrome”). See also section 2.

You should immediately inform your doctor if any of the following serious side effects occur:

• fever, chills, sore throat, cough, mouth ulcers or any other signs of infection (including blood infections (sepsis));
• bleeding or bruising without injury;
• chest pain or leg pain;
• shortness of breath;
• bone pain, muscle weakness, confusion or fatigue, which may result from high calcium levels in the blood.

Lenalidomide G.L. may reduce the number of white blood cells that fight infection, as well as
blood cells that help blood to clot (platelets), which may lead to bleeding disorders, such as nosebleeds and bruising. Lenalidomide G.L. may also
cause blood clots in veins (thrombosis).

Other side effects
Please note that in a small number of patients, other types of cancer may develop, and it is possible that this risk may be increased by treatment with Lenalidomide G.L.
Therefore, your treating physician should carefully evaluate the benefits and risks before prescribing Lenalidomide G.L. to a patient.

Very common side effects (may occur in more than 1 out of 10 people):

• decreased number of red blood cells, which may cause anaemia leading to tiredness and weakness;
• skin rashes, itching;
• muscle cramps, muscle weakness, muscle pain, myalgia, bone pain, joint pain, back pain, limb pain;
• generalised swelling, including swelling of hands and feet;
• weakness, fatigue;
• flu and flu-like symptoms, including fever, muscle pain, headache, earache, cough and chills;
• tingling, numbness or burning sensation of the skin, pain in hands or feet, dizziness, tremor;
• decreased appetite, altered taste sensation;
• worsening of pain, increase in tumour size or redness around the tumour;
• weight loss;
• constipation, diarrhoea, nausea, vomiting, abdominal pain, heartburn;
• low levels of potassium, calcium and/or sodium in the blood;
• underactive thyroid gland;
• leg pain (which may be a sign of thrombosis), chest pain or shortness of breath (which may be symptoms of blood clots in the lungs, known as pulmonary embolism);
• all types of infections, including sinusitis, lung infections and upper respiratory tract infections;
• shortness of breath;
• blurred vision;
• cloudy vision (cataract);
• kidney problems, including abnormal kidney function or inability to maintain normal kidney function;
• abnormal liver test results;
• increased values in liver function tests;
• changes in blood proteins leading to blood vessel swelling (vasculitis);
• increased blood sugar levels (hyperglycaemia);
• decreased blood sugar levels;
• headache;
• nosebleeds;
• dry skin;
• depression, mood changes, sleep disturbances;
• cough;
• low blood pressure;
• vague feeling of physical discomfort, malaise;
• painful inflammation of the mouth, dry mouth;
• dehydration.

Common side effects (may occur in less than 1 out of 10 people):

• breakdown of red blood cells (haemolytic anaemia);
• certain types of skin tumours;
• bleeding from gums, stomach or intestines;
• increased blood pressure, slow, fast or irregular heartbeat;
• increased levels of substances produced by normal and abnormal breakdown of red blood cells;
• increased levels of a protein indicating inflammation in the body;
• darkening of the skin; skin discolouration due to bleeding under the skin, usually caused by bruising; blood-filled skin swelling, bruising;
• increased levels of uric acid in the blood;
• skin eruptions, redness of the skin, blistering, peeling or flaking of the skin, hives;
• itching, excessive sweating, night sweats;
• difficulty swallowing, sore throat, problems with voice quality or voice changes;
• runny nose (rhinitis);
• passing significantly more or significantly less urine than normal, or inability to control the timing of urination;
• blood in the urine;
• shortness of breath, especially when lying down (which may be a symptom of heart failure);
• erectile dysfunction;
• stroke, fainting, dizziness (inner ear disorders causing a spinning sensation), transient loss of consciousness;
• chest pain spreading to arms, neck, jaw, back or abdomen, sweating, breathlessness, nausea or vomiting, which may be symptoms of a heart attack (myocardial infarction);
• muscle weakness, lack of energy;
• neck pain, chest pain;
• chills;
• joint swelling;
• slowing or blockage of bile flow from the liver;
• low levels of phosphates or magnesium in the blood;
• difficulty speaking;
• liver damage;
• balance disorders, difficulty moving;
• hearing loss, tinnitus (ringing in the ears);
• nerve pain, unpleasant abnormal sensations, especially in response to touch;
• excess iron in the body;
• thirst;
• confusion;
• toothache;
• falls that may lead to injury.

Uncommon side effects (may occur in less than 1 out of 100 people):

• bleeding inside the skull;
• circulation problems;
• loss of vision;
• loss of sexual desire (libido);
• passing large amounts of urine, accompanied by bone pain and weakness, which may be symptoms of kidney disease (Fanconi syndrome);
• yellowing of the skin, mucous membranes or eyes (jaundice), pale stools, dark urine, itching, rash, abdominal pain or swelling – may be symptoms of liver damage (liver failure);
• abdominal pain, bloating or diarrhoea, which may be symptoms of inflammation of the large intestine (colitis or diverticulitis);
• kidney tubular cell damage (known as tubular necrosis);
• skin colour changes, sensitivity to sunlight;
• tumour lysis syndrome – metabolic complications that may occur during cancer treatment, and sometimes even without treatment. These complications are caused by the breakdown products of dying tumour cells and may include: changes in blood chemistry; high levels of potassium, phosphate and uric acid, and low calcium levels, leading to kidney dysfunction, heart rhythm disturbances, seizures, and sometimes death;
• high blood pressure in the blood vessels leading to the lungs (pulmonary hypertension).

Side effects with unknown frequency (frequency cannot be estimated from available data):

• sudden or gradually worsening upper abdominal and/or back pain lasting for several days, often accompanied by nausea, vomiting, fever and rapid heartbeat – these symptoms may occur in association with pancreatitis;
• wheezing, shortness of breath or dry cough, possibly due to inflammation of lung tissue;
• rare cases of muscle breakdown (rhabdomyolysis – muscle pain, weakness or swelling) have been observed, which may lead to kidney problems; some of these occurred when lenalidomide was administered concomitantly with a statin (a type of medicine that lowers cholesterol levels in the blood);
• skin disease caused by inflammation of small blood vessels, associated with joint pain and fever (leukocytoclastic vasculitis);
• perforation of the stomach or intestinal wall, which may lead to severe infection. Inform your doctor if you experience severe stomach pain, fever, nausea, vomiting, blood in the stool or changes in bowel function;
• viral infections, including herpes zoster (a viral disease causing a painful skin rash with blisters) and reactivation of hepatitis B virus infection (which may cause yellowing of the skin and eyes, dark urine, right-sided abdominal pain, fever, nausea and vomiting);
• organ transplant rejection (e.g. kidney, heart).

Reporting of side effects
If you experience any undesirable effects, including any side effects not listed in this leaflet, you should inform your doctor, pharmacist or nurse. Side effects can be reported directly to the Department of Monitoring Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Al. Jerozolimskie 181C,
02-222 Warsaw
Tel: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorisation holder.
By reporting side effects, you help provide more information on the safety of this medicine.

5. How to store Lenalidomide G.L.

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the blister and carton after:
"EXP". The expiry date refers to the last day of the stated month.
There are no special storage instructions for this medicine.
Do not use this medicine if you notice any damage or signs of tampering with the packaging.
Medicines should not be disposed of via wastewater or household waste. Unused medicines should be returned to a pharmacy. This will help protect the environment.

6. Contents of the pack and other information

What Lenalidomide G.L. contains
Lenalidomide G.L., 5 mg, hard capsules

• The active substance is lenalidomide. Each capsule contains 5 mg of lenalidomide.
• Other ingredients are:
  • capsule contents: lactose (see section 2), microcrystalline cellulose, sodium croscarmellose, magnesium stearate
  • capsule shell: brilliant blue FCF (E 133), iron oxide red (E 172), iron oxide yellow (E 172), titanium dioxide (E 171), gelatin
  • printing ink: shellac, propylene glycol, iron oxide black (E 172), potassium hydroxide

Lenalidomide G.L., 10 mg, hard capsules

• The active substance is lenalidomide. Each capsule contains 10 mg of lenalidomide.
• Other ingredients are:
  • capsule contents: lactose (see section 2), microcrystalline cellulose, sodium croscarmellose, magnesium stearate
  • capsule shell: iron oxide black (E 172), iron oxide yellow (E 172), titanium dioxide (E 171), gelatin
  • printing ink: shellac, propylene glycol, iron oxide black (E 172), potassium hydroxide

Lenalidomide G.L., 15 mg, hard capsules

• The active substance is lenalidomide. Each capsule contains 15 mg of lenalidomide.
• Other ingredients are:
  • capsule contents: lactose (see section 2), microcrystalline cellulose, sodium croscarmellose, magnesium stearate
  • capsule shell: iron oxide black (E 172), iron oxide red (E 172), iron oxide yellow (E 172), titanium dioxide (E 171), gelatin
  • printing ink: shellac, propylene glycol, iron oxide black (E 172), potassium hydroxide

Lenalidomide G.L., 25 mg, hard capsules

• The active substance is lenalidomide. Each capsule contains 25 mg of lenalidomide.
• Other ingredients are:
  • capsule contents: lactose (see section 2), microcrystalline cellulose, sodium croscarmellose, magnesium stearate
  • capsule shell: titanium dioxide (E 171), gelatin
  • printing ink: shellac, propylene glycol, iron oxide black (E 172), potassium hydroxide

What Lenalidomide G.L. looks like and contents of the pack
Lenalidomide G.L., 5 mg, hard capsules
Dark green, opaque cap and flesh-coloured, opaque body, capsule size 2,
18-19 mm, with black print "LP" on the cap and "638" on the body.
Lenalidomide G.L., 10 mg, hard capsules
Intense yellow, opaque cap and grey, opaque body, capsule size 0,
21-22 mm, with black print "LP" on the cap and "639" on the body.
Lenalidomide G.L., 15 mg, hard capsules
Light bronze, opaque cap and light grey, opaque body, capsule size 2,
18-19 mm, with black print "LP" on the cap and "640" on the body.
Lenalidomide G.L., 25 mg, hard capsules
White, opaque cap and white, opaque body, capsule size 0, 21-22 mm,
with black print "LP" on the cap and "642" on the body.
Cardboard box containing PVC/ACLAR/Aluminium blisters with 7 capsules each.
Pack sizes of 7 or 21 capsules.
Not all pack sizes may be marketed.

Marketing Authorisation Holder
G.L. Pharma GmbH
Schlossplatz 1
8502 Lannach
Austria

Manufacturer/Importer
Pharmadox Healthcare Ltd
KW20A Kordin Industrial Park,
Paola PLA 3000, Malta
Adalvo Ltd
Malta Life Sciences Park
Building 1, Level 4
Sir Temi Zammit Buildings
San Gwann Industrial Estate,
San Gwann SGN 3000, Malta

For further information on this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
G.L. PHARMA POLAND Sp. z o.o.
Al. Jana Pawła II 61/313
01-031 Warsaw, Poland
Tel: 022/ 636 52 23; 636 53 02
[email protected]